DexCom Q1 earnings mixed, co reiterates fiscal year 2022 guidance
Tatiana/iStock via Getty Images


DexCom (NASDAQ:DXCM) on Thursday reported a mixed set of Q1 earnings, with non-GAAP EPS of $0.32 missing estimates by $0.20 but revenue of $628.8M beating expectations by $4.83M.
The company reiterated its guidance for fiscal year 2022. Revenue is expected to be in the range of about $2.82B-$2.94B, vs consensus revenue estimates of $2.92B.

San Diego, Calif.-based DXCM develops diabetes care technology. Its products include glucose monitoring and reading systems, sensors and transmitters, along with software and mobile applications.
DXCM said Q1 U.S. revenue grew 18% and international revenue grew 43%.
"Volume growth in conjunction with strong new customer additions continues to be the primary driver of revenue growth as awareness of real-time CGM increases," the company said.
As of March 31, DXCM had cash and cash equivalents of $2.69B.
The company is gearing up to launch its new wearable Dexcom ONE continuous glucose monitoring system in the UK in May.
DXCM stock -2.2% to $403.99 in aftermarket trading. The company last month opted for a 4-for-1 stock split.